Hipertensión arterial resistente

1 Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol 2018; 71(19):2275–2279]. J Am Coll Cardiol 2018; 71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006

2. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientifi c statement from the American Heart Association. Hypertension 2018; 72(5):e53–e90. doi:10.1161/HYP.0000000000000084

3. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19):2560–2572. doi: 10.1001/jama.289.19.2560. Erratum in: JAMA. 2003 Jul 9; 290(2):197. PMID: 12748199

4. Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation 2018; 137(2):109–118 doi:10.1161/CIRCULATIONAHA.117.032582

5. Centers for Disease Control and Prevention. About multiple causes of death, 1999–2020. https://wonder.cdc.gov/mcd-icd10.html. Accessed December 28, 2022.

6. Kirkland EB, Heincelman M, Bishu KG, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003–2014. J Am Heart Assoc 2018; 7(11):e008731 doi:10.1161/JAHA.118.008731

7. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021; 99(3S):S1–S87. doi:10.1016/j.kint.2020.11.003

8. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control [published correction appears in N Engl J Med 2017; 377(25):2506]. N Engl J Med 2015; 373(22):2103–2116. doi:10.1056/NEJMoa1511939

9. Cheung AK, Rahman M, Reboussin DM, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol 2017; 28(9):2812–2823. doi:10.1681/ASN.2017020148

10. ElSayed NA, Aleppo G, Aroda VR, et al. Summary of revisions: standards of care in diabetes—2023. Diabetes Care 2023; 46[suppl1]: S5–S9. https://doi.org/10.2337/dc23-Srev

11. Centers for Disease Control and Prevention. Estimated hypertension prevalence, treatment, and control among US adults. https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html. Accessed December 28, 2022.

12. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011; 57(6):1076–1080. doi:10.1161/HYPERTENSIONAHA.111.170308

13. Thomas G, Xie D, Chen HY, et al. Prevalence and prognostic signifi cance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insuffi ciency Cohort study. Hypertension 2016; 67(2):387–396. doi:10.1161/HYPERTENSIONAHA.115.06487

14. ALLHAT Offi cers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published correction appears in JAMA 2003; 289(2):178] [published correction appears in JAMA 2004;291(18):2196]. JAMA 2002; 288(23):2981–2997. doi:10.1001/jama.288.23.2981 15. Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014; 64(5):1012–1021. doi:10.1161/HYPERTENSIONAHA.114.03850

16. Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med 2014; 127(1):71–81.e1. doi:10.1016/j.amjmed.2013.07.038

17. Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens 2017; 35(12): 2346–2357. doi:10.1097/HJH.0000000000001502

18. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes  Yugar-Toledo JC, Moreno H. Intensive monitoring of adherence to treatment helps to identify “true” resistant hypertension. J Clin Hypertens (Greenwich) 2009; 11(4):183–191. doi:10.1111/j.1751-7176.2009.00102.x

19. Ruzicka M, Leenen FHH, Ramsay T, et al. Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med 2019; 179(10):1433–1434. doi:10.1001/jamainternmed.2019.1455

20. Naik AD, Kallen MA, Walder A, Street RL Jr. Improving hypertension control in diabetes mellitus: the effects of collaborative and proactive health communication. Circulation 2008; 117(11):1361–1368. doi:10.1161/CIRCULATIONAHA.107.724005

21. Beckett L, Godwin M. The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord 2005; 5(1):18. doi:10.1186/1471-2261-5-18

22. Shimbo D, Abdalla M, Falzon L, Townsend RR, Muntner P. Role of ambulatory and home blood pressure monitoring in clinical practice: a narrative review. Ann Intern Med 2015; 163(9):691–700. doi:10.7326/M15-1270

23. Cohen JB, Lotito MJ, Trivedi UK, Denker MG, Cohen DL, Townsend RR. Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis. Ann Intern Med 2019;170(12):853–862. doi:10.7326/M19-0223

24. Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: international database of home blood pressure in relation to cardiovascular outcome. Hypertension 2014;63(4):675–682. doi:10.1161/HYPERTENSIONAHA.113.02741

25. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich) 2013; 15(1):14–33. doi:10.1111/jch.12049

26. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124(9):1046–1058. doi:10.1161/CIRCULATIONAHA.111.030189

27. Parikh JS, Randhawa AK, Wharton S, Edgell H, Kuk JL. The association between antihypertensive medication use and blood pressure is infl uenced by obesity. J Obes 2018; 2018:4573258. doi:10.1155/2018/4573258

28. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1):3–10. doi:10.1056/NEJM200101043440101

29. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54(3):475–481. doi:10.1161/HYPERTENSIONAHA.109.131235